Glucoză Stada Hemofarm (Glucose Monohydrate)

Glucoză Stada Hemofarm is used in clinical settings where rapid glucose supplementation is required.

• Correction of acute hypoglycemia in patients who cannot take oral glucose, such as those who are unconscious or intubated.
• Supplementation of carbohydrate calories during operative procedures or anesthesia to maintain blood glucose stability.
• Adjunct to total parenteral nutrition regimens, providing a readily available source of glucose for metabolic needs.
• Assistance in the management of electrolyte disturbances that may accompany low plasma glucose levels, such as potassium shifts.
• Facilitation of certain diagnostic tests, for example glucose tolerance assessments, where a precise intravenous glucose dose is required.

When administered intravenously, glucose monohydrate can produce a range of physiological responses, most of which are mild and transient.

Common

• Temporary feeling of warmth or flushing at the infusion site.
• Mild nausea or abdominal discomfort.
• Transient increase in blood glucose levels.
• Headache or dizziness, especially if administered rapidly.

Serious

• Hyperglycemia leading to osmotic diuresis.
• Hypotension due to rapid infusion of hypotonic solution.
• Allergic reactions such as rash, itching, or anaphylaxis.
• Electrolyte imbalance, particularly low potassium (hypokalemia).
• Pulmonary edema in patients with compromised cardiac function.

Healthcare providers should observe several precautions before and during the administration of Glucoză Stada Hemofarm to ensure patient safety.

• Verify patient’s blood glucose level and overall metabolic status prior to infusion.
• Use aseptic technique and inspect the solution for particulate matter or discoloration.
• Adjust infusion rate according to patient age, weight, and cardiac function.
• Monitor vital signs and blood glucose frequently during and after administration.
• Avoid use in patients with known hypersensitivity to glucose solutions.
• Consider renal or hepatic impairment, which may affect glucose metabolism.
• Ensure compatible IV fluids are used to prevent precipitation.

Glucose monohydrate may interact with other intravenous agents or medications, influencing their efficacy or safety.

Avoid

• Co‑administration with rapid‑acting insulin without close glucose monitoring.
• Simultaneous infusion of high‑dose potassium chloride, which can increase the risk of hyperkalemia.
• Mixing with calcium‑containing solutions that may cause precipitation.

Use with caution

• Concurrent use of diuretics that can alter electrolyte balance.
• Administration alongside beta‑blockers, which may mask signs of hypoglycemia.
• Use in patients receiving corticosteroids, as they can raise blood glucose levels.
• Combination with other hyperosmolar solutions, requiring careful monitoring of fluid status.